1 / 27

ABPI Scotland: Medicines in Scotland

ABPI Scotland: Medicines in Scotland. What is ABPI?. Membership body of the Pharmaceutical Industry – statutory negotiating body Represents majority of research based companies Members supply over 90% of medicines to the NHS

avon
Download Presentation

ABPI Scotland: Medicines in Scotland

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ABPI Scotland:Medicines in Scotland

  2. What is ABPI? • Membership body of the Pharmaceutical Industry – statutory negotiating body • Represents majority of research based companies • Members supply over 90% of medicines to the NHS • 2/3rd of all research and development of new medicines is undertaken by member companies • ABPI Code of Practice - administered by PMCPA http://www.pmcpa.org.uk/Pages/default.aspx

  3. Trust & reputation? • Declaration of payments • Pads & pens • Clinical trial transparency • Interaction with patient groups

  4. ABPI in Scotland • Participation in National groups – SMC, PASAG, PAPIG, LiSAB, Medical Directors group, Strategic Engagement Group, SIGN implementation group, NRS Industry partnership group • 2 strategic groups – SAVG, SLSG • 9 Therapy specific groups • Collaboration - > A Common Understanding 2012 – Working together for Patients

  5. Investment • The pharmaceutical industry globally invests more in research and development than any other industry – £12.1 million every day. • The pharmaceutical industry employs around 25,000 people in R&D in the UK (Business Enterprise Research and Development (2008, 2009, 2010) 2010 released Nov 2011 – Office for National Statistics (ONS).

  6. ABPI: Key issues... • Uptake and innovation • Pricing: is it a barrier to uptake? • Clinical research: are we under threat?

  7. ABPI: Key issues... • Uptake and innovation • Low and slow

  8. Market share of innovative products in the UK is behind European peers and deteriorating Market share for products -brands and generics- launched in the past 5 years by value (%)(1) Branded medicines launched in the past 5 years are expected to account for 5% of spend only by 2015, similar to previous years’ levels NICE’s ~40% rejection rate and NICE ‘blight’ lead to delays and limited access as well as poor performance in innovation uptake(2) • IMS Health World Review Analyst, 2010 • OHE analysis 2012

  9. Uptake of new medicines in Scotland (OHE stats)

  10. Uptake of new medicines in Scotland... Scottish Government recognised there is a problem: • CEL 17 (and follow-up CMO) • Statement of Intent • New medicines review (recently announced) Scottish Parliament has recognised there is a problem: • Public Petitions Committee inquiry • Health & Sport Committee Inquiry (ongoing)

  11. ABPI: Key issues... • Pricing: is it a barrier to uptake?

  12. Overall, UK spending on medicines as a percentage of GDP (developed countries)… Spending on medicines as a percentage of GDP in various countries in 2011(1) If Spain cut down pharmaceutical spend by 20%, the proportion of GDP would be 1.2%, i.e. still higher than in the UK’s • (1) IMS Health World Review Analyst 2012. OECD Health Database.  All data accessed March 2012

  13. The UK has severe uptake issues in critical therapy areas Spend per capita on cancer medicines launched in the previous 5 years in Europe (£)(1) £ The UK has the lowest per capita spend in cancer medicines launched in the past 5 years • IMS Midas 2006

  14. Poor uptake of innovative medicines in the UK leads to poor patient outcomes 5 year survival rates in cancer in Europe, men and women (%)(1) The UK has the lowest survival rates in cancer in Europe • Eurocare 4 2009

  15. Branded pharmaceutical prices are amongst the lowest in developed countries Position of the UK in the ranking of branded pharmaceutical prices by year(1) (1) OHE, 11th Report (2004-2010); 5th Report (2000 - 2003); 2011: OHE calculations based on IMS and PCA data. Note: blank cell = Not available Notes: Table includes the years prior to PPRS negotiations (2003/2004; 2007/2008) as well as for 2010 and 2011 Exchange rate used: Average of Q4 of every year. In a recent report (September 2012) The European Commission has indicated that the UK is a highly efficient medicines market

  16. The UK has among the highest penetration of and use generics across European countries, c. 65% Generics market share in Europe by volume % 66% 65% 65% 64% 63% 53% 52% 49% 49% 47% 45% 45% 43% 42% 40% 39% 36% 35% 34% MEAN UK DE CA DK NE SE TK FI FR PT ES NO IE IT CH AT BE GR % NON GENERIC PRODUCTS  % GENERIC PRODUCTS Source: IMS 2012 (2011 data)

  17. Betweeen 2011 and 2015 (at list prices - OHE)... • Total medicines bill for NHSScotland is projected to increase by 2.9% - 3.9% (£1.37bn - £1.43bn) • Branded medicines bill for NHSScotland is projected to increase by 0.5% - 1.5% (£0.99bn – £1.03bn)

  18. Volume, not cost as the main driver of rise...? • £100m front-line cuts for Scotland’s NHSScotland in Sunday (Nov 25th 2012) • “... On drugs and prescribing, NHS boards claimed many of the savings would accrue by switching from costly branded medicines to generic drugs, no longer covered by commercial patents. “However, they also said reviews were being undertaken by GPs and hospitals to review the volume of prescriptions, the biggest cost driver in recent years.”

  19. ABPI: Key issues... • Clinical research: are we under threat?

  20. While the pharma sector contributes 1 in 2 R&D pounds in the UK(1), it is in decline National origin of leading 100 global medicines by sales 2004–2011 (2) UK Global Share of patients in clinical trials 2000 – 2010(3) -77% % of global sales of leading 100 medicines by country of origin 6% 2% 1.4% 2000 2006 2010 Twelve major pharmaceutical site closures between 1996 and 2012(4) • ONS UK Business Enterprise Research and Development, 2009 • Department of Health, MISG, Pharmaceutical Industry: Competitiveness and Performance Indicators 2009 • Centre for Medicines Research (www.cmr.org); Global Clinical Performance Metrics Database; Kinapse report • ABPI analysis

  21. The UK currently has a prominent position in global launch sequences • The UK is an early launch market in global pharmaceutical launch sequences • 68% of pharmaceutical companies launch new medicines in the UK first (first, second or third market worldwide) • 66% of companies anticipate that government’s proposals for a new pricing scheme will adversely affect the UK’s global position in the launch sequence • Source: Industry market research, Feb-March 2012

  22. Don’t just take our word for it... • Evidence given to the Health & Sport Committee inquiry into new medicines from: • a group of 17 oncologists • Oral evidence of a further oncologist • Cancer Research UK: “The UK’s lower rate of uptake for new cancer drugs may be damaging to our ability to design and run internationally competitive studies. If very few patients can get licensed drugs that are the standard of care outside the UK, this could lead to fewer industry-supported trials being conducted in the UK”

  23. The future…

  24. The future… • Harder and more expensive to develop medicines – no more blockbusters… • Personalised medicines… • Less money, more patients… • Health & social care integration • Long term conditions • Move away from acute care

  25. The future… • Access to new medicines reviews… • Barriers to access? • Closer collaboration and partnership working…?

  26. Thank you… Keith Small – ksmall@abpi.org.uk

More Related